MétaCan
Menu
Back to cohort
Record W4403833735 · doi:10.1681/asn.2024qdwvz5bg

VALIANT: A Randomized, Multicenter, Double-Blind, Placebo (PBO)-Controlled, Phase 3 Trial of Pegcetacoplan for Patients with Native or Post-transplant Recurrent Glomerulopathy (C3G) or Primary Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)

2024· article· en· W4403833735 on OpenAlexaff
Carla Nester, Andrew S. Bomback, María Gema Ariceta Iraola, Yahsou Delmas, Bradley P. Dixon, Daniel P. Gale, Larry A. Greenbaum, Seung Hyeok Han, Nicole M. Isbel, Christoph Licht, Antonio Mastrangelo, Masashi Mizuno, Maria Izabel Neves de Holanda, Matthew C. Pickering, Giuseppe Remuzzi, Nicole C. A. J. van de Kar, Marina Vivarelli, Patrick D. Walker, Dean Wallace, Daniel Zecher, Li Li, Zhongshen Wang, Luis López Lázaro, Johan Szamosi, Fádi Fakhouri

Bibliographic record

VenueJournal of the American Society of Nephrology · 2024
Typearticle
Languageen
FieldImmunology and Microbiology
TopicComplement system in diseases
Canadian institutionsHospital for Sick Children
Fundersnot available
KeywordsMembranoproliferative glomerulonephritisMedicineGlomerulopathyPlaceboImmune systemDouble blindInternal medicineImmunologyGastroenterologyUrologyGlomerulonephritisKidneyPathology

Abstract

fetched live from OpenAlex

Background: VALIANT (NCT05067127) is a double-blind, PBO-controlled trial investigating the efficacy/safety of pegcetacoplan (PEG), a C3/C3b inhibitor, in adolescents (≥12 yrs) and adults with native or post-transplant recurrent C3G or primary IC-MPGN. Methods: Patients (pts) received PEG (SC infusion 2x/wk) or PBO (randomized 1:1) for 26 wks. The primary endpoint was log-transformed ratio of uPCR at wk 26 vs. baseline to measure proteinuria reduction vs. PBO. Results: 124 pts were randomized to PEG (n=63) or PBO (n=61). The primary endpoint was met:68.3% (95% CI –76.3, –57.7) uPCR reduction in PEG vs. PBO arms at wk 26 (p<0.0001; Table). Results were consistent across all subgroups (disease type, age, and transplant status). Robust reductions in C3c staining and clinically meaningful eGFR stabilization were observed with PEG vs. PBO (Table). Treatment-emergent AE frequency and severity were similar between arms. None of the 4 serious infections (3 PEG; 1 PBO) were attributed to encapsulated bacteria. 1 death occurred in the PEG arm due to COVID-19 pneumonia (unrelated to PEG). Conclusion: PEG, a C3/C3b inhibitor, is the first therapy to achieve significant and clinically meaningful reductions in proteinuria (68.3% vs. PBO) and C3c staining and eGFR stabilization, compared with PBO in pts ≥12 yrs with C3G or primary IC-MPGN and was well tolerated.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.036
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.000
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0040.002
Bibliometrics0.0000.000
Science and technology studies0.0000.002
Scholarly communication0.0000.000
Open science0.0010.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.028
GPT teacher head0.311
Teacher spread0.284 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations24
Published2024
Admission routes1
Has abstractyes

Explore more

Same venueJournal of the American Society of NephrologySame topicComplement system in diseasesFrench-language works237,207